Extended Data Fig. 5: T1 and T3 cells proliferate and control BV173 ALL in vivo.

(a) Bioluminescence imaging (BLI) analysis of NSG mice on day 9 after BV173^ffluc-eGFP cell injection, one day prior to T-cell therapy. Data were pooled from two independent experiments, untreated n = 10, 1G4 n = 7, T1 n = 8, T3 n = 9. Data analysis by one-way ANOVA with Tukey’s multiple comparison test. (b,c) The percentage of human CD3⁺ (b) and CD8⁺ cells (c) in PB of mice analyzed at indicated time points out of total CD45⁺ human and CD45⁺ mice leukocytes. (d) Percent cells expressing T1, T3 and 1G4 TCRs among human CD8⁺ T cells throughout the experiment. Data in b-d are shown as mean ± s.e.m., n = 5/group. (e) Flow cytometry plots showing bone-marrow tumor burden in five T3-treated mice analysed on day 60 (M1-M5), compared to the 1G4-treated or untreated mouse at time of sacrifice (day 21). Threshold for positive leukemia detection was set as GFP⁺ cells ≥ 0.01% of live viable cells. (f) Expression of HLA-A2 and TdT in leukemia cells harvested from the bone marrow of untreated, 1G4 and the one T3-treated mouse with detectable tumor burden (M5). Light gray histograms represent negative control. (g) Numbers of TCR-transduced CD8⁺ cells in blood of T3-treated mice on day 60 (n = 5, M1-4: black circles, M5: red circle). Box plots in (a) and (g) show interquartile range (25^th to 75^th percentile) with central bar indicating the median and whiskers indicating the range while dots represent data from individual mice.

Source data